1
|
Donadio JV and Grande JP: IgA nephropathy.
N Engl J Med. 347:738–748. 2002. View Article : Google Scholar : PubMed/NCBI
|
2
|
D’Amico G: Influence of clinical and
histological features on actuarial renal survival in adult patients
with idiopathic IgA nephropathy, membranous nephropathy, and
membranoproliferative glomerulonephritis: survey of the recent
literature. Am J Kidney Dis. 20:315–323. 1992.
|
3
|
Alamartine E, Sabatier JC, Guerin C,
Berliet JM and Berthoux F: Prognostic factors in mesangial IgA
glomerulonephritis: an extensive study with univariate and
multivariate analyses. Am J Kidney Dis. 18:12–19. 1991. View Article : Google Scholar : PubMed/NCBI
|
4
|
Odum J, Peh CA, Clarkson AR, et al:
Recurrent mesangial IgA nephritis following renal transplantation.
Nephrol Dial Transplant. 9:309–312. 1994.PubMed/NCBI
|
5
|
Sanfilippo F, Croker BP and Bollinger RR:
Fate of four cadaveric donor renal allografts with mesangial IgA
deposits. Transplantation. 33:370–376. 1982. View Article : Google Scholar : PubMed/NCBI
|
6
|
Koselj M, Rott T, Vizjak A and Kveder R:
IgA nephropathy as a donor-transmitted disease in renal transplant
recipients. Transplant Proc. 23:2643–2646. 1991.PubMed/NCBI
|
7
|
Shiraishi S, Tomoda K, Matsumoto A,
Kyomoto R and Yamashita T: Investigation of the local provocation
test to PPP and IgA nephritis. Acta Otolaryngol Suppl. 523:178–181.
1996.PubMed/NCBI
|
8
|
Yamabe H, Osawa H, Inuma H, et al:
Deterioration of urinary findings after tonsil stimulation in
patients with IgA nephropathy. Acta Otolaryngol Suppl. 523:169–171.
1996.PubMed/NCBI
|
9
|
Pozzi C, Andrulli S, Del Vecchio L, et al:
Corticosteroid effectiveness in IgA nephropathy: long term results
of a randomized, controlled trial. J Am Soc Nephrol. 15:157–163.
2004. View Article : Google Scholar : PubMed/NCBI
|
10
|
Barratt J and Feehally J: Treatment of IgA
nephropathy. Kidney Int. 69:1934–1938. 2006. View Article : Google Scholar
|
11
|
Feehally J, Barratt J, Coppo R, Cook T and
Roberts I: International IgA Nephropathy Network: International IgA
nephropathy network clinico-pathological classification of IgA
nephropathy. Contrib Nephrol. 157:13–18. 2007.PubMed/NCBI
|
12
|
Working Group of the International IgA
Nephropathy Network and the Renal Pathology Society. Cattran DC,
Coppo R, Cook HT, et al: The Oxford classification of IgA
nephropathy: rationale, clinicopathological correlations, and
classification. Kidney Int. 76:534–545. 2009. View Article : Google Scholar : PubMed/NCBI
|
13
|
Working Group of the International IgA
Nephropathy Network and the Renal Pathology Society. Roberts IS,
Cook HT, Troyanov S, et al: The Oxford classification of IgA
nephropathy: pathology definitions, correlations and
reproducibility. Kidney Int. 76:546–556. 2009. View Article : Google Scholar : PubMed/NCBI
|
14
|
Yoshida M, Hatano N, Nishiumi S, Irino Y,
Izumi Y, Takenawa T and Azuma T: Diagnosis of gastroenterological
diseases by metabolome analysis using gas chromatography-mass
spectrometry. J Gastroenterol. 47:9–20. 2012. View Article : Google Scholar : PubMed/NCBI
|
15
|
Tomosugi N, Kawabata H, Wakatabe R,
Higuchi M, Yamaya H, Umehara H and Ishikawa I: Detection of serum
hepcidin in renal failure and inflammation by using ProteinChip
System. Blood. 108:1381–1387. 2006. View Article : Google Scholar : PubMed/NCBI
|
16
|
Kanmura S, Uto H, Kusumoto K, et al: Early
diagnostic potential for hepatocellular carcinoma using the SELDI
ProteinChip system. Hepatology. 45:948–956. 2007. View Article : Google Scholar : PubMed/NCBI
|
17
|
Kanmura S, Uto H, Sato Y, et al: The
complement component C3a fragment is a potential biomarker for
hepatitis C virus-related hepatocellular carcinoma. J
Gastroenterol. 45:459–467. 2010. View Article : Google Scholar : PubMed/NCBI
|
18
|
Schägger H: Tricine-SDS-PAGE. Nat Protoc.
1:16–22. 2006.
|
19
|
Abou-Ragheb HH, Williams AJ, Brown CB and
Milford-Ward A: Plasma levels of the anaphylatoxins C3a and C4a in
patients with IgA nephropathy/Henoch-Schönlein nephritis. Nephron.
62:22–26. 1992.
|
20
|
Wyatt RJ, Kanayama Y, Julian BA, Negoro N,
Sugimoto S, Hudson EC and Curd JG: Complement activation in IgA
nephropathy. Kidney Int. 31:1019–1023. 1987. View Article : Google Scholar : PubMed/NCBI
|
21
|
Matsuda M, Shikata K, Wada J, Sugimoto H,
Shikata Y, Kawasaki T and Makino H: Deposition of mannan binding
protein and mannan binding protein-mediated complement activation
in the glomeruli of patients with IgA nephropathy. Nephron.
80:408–413. 1998. View Article : Google Scholar : PubMed/NCBI
|
22
|
Endo M, Ohi H, Ohsawa I and Fujita T,
Matsushita M and Fujita T: Glomerular deposition of mannose-binding
lectin (MBL) indicates a novel mechanism of complement activation
in IgA nephropathy. Nephrol Dial Transplant. 13:1984–1990. 1998.
View Article : Google Scholar : PubMed/NCBI
|
23
|
Espinosa M, Ortega R, Gomez-Carrasco JM,
Lopez-Rubio F, Lopez-Andreu M, Lopez-Oliva MO and Aljama P:
Mesangial C4d deposition: a new prognostic factor in IgA
nephropathy. Nephrol Dial Transplant. 24:886–891. 2009. View Article : Google Scholar : PubMed/NCBI
|
24
|
Roos A, Rastaldi MP, Calvaresi N, et al:
Glomerular activation of the lectin pathway of complement in IgA
nephropathy is associated with more severe renal disease. J Am Soc
Nephrol. 17:1724–1734. 2006. View Article : Google Scholar : PubMed/NCBI
|
25
|
Pfeifer PH, Kawahara MS and Hugli TE:
Possible mechanism for in vitro complement activation in blood and
plasma samples: futhan/EDTA controls in vitro complement
activation. Clin Chem. 45:1190–1199. 1999.PubMed/NCBI
|
26
|
Morgan E, Varro R, Sepulveda H, et al:
Cytometric bead array: a multiplexed assay platform with
applications in various areas of biology. Clin Immunol.
110:252–266. 2004. View Article : Google Scholar : PubMed/NCBI
|